Doxazosin Mesylate CAS:77883-43-3 Manufacturer Supplier

Doxazosin mesylate is a quinazoline compound that is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. Doxazosin mesylate is a new generation of quinazolone α1 receptor blocker developed by the Pfizer company (United States), It has a long half-life, exerting its effects of dilating the blood vessels, reducing the vascular resistance and lowering the blood pressure through blocking the a 1 receptor. It has been recommended abroad as first-line clinical drugs of anti-hypertension and treatment of prostate disease.

Order or Request Quote

Product Detail

Product Tags

Application and Effect

Doxazosin mesylate is a new highly selective α1 receptor blockers, having a significant effect of causing reduction in blood pressure while having good effect of alleviating lipid metabolism. It can significantly reduce serum triglycerides and total cholesterol; it can also selectively block the a1 adrenergic receptor of prostate smooth muscle matrix, capsule and bladder neck, alleviating the symptoms of benign prostatic hyperplasia patients, further significantly slowing down the effect of benign prostatic hyperplasia, especially having good effect on the treatment of dysuria caused by simple prostatic hyperplasia. It has a long half-life.There may be dizziness, dry mouth, headache, palpitations, fatigue, the symptoms are mild, bearable, disappear within about 1 week, without special treatment. No postural hypotension occurred.